Revolade (eltrombopag) study for children with aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial is for children and teenagers (ages 6 to 17) with aplastic anemia who are starting eltrombopag (Revolade) for the first time, taken together with ATG (a medicine that helps the immune system). The study will monitor how well the treatment works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You have aplastic anemia (a condition where your bone marrow doesn't make enough blood cells).
- You are about to start eltrombopag (Revolade) for the first time, and it will be combined with a medicine called ATG (anti-thymocyte globulin).
- You have not had ATG alone (without eltrombopag) before.
- You do not have a type of aplastic anemia that is passed down through families (congenital).
- You do not have a blood disorder called myelodysplastic syndrome (MDS).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called avatrombopag to see if it can help increase the number of platelets (cells that help blood clot) in adults with aplastic anemia who have not improved with standard treatments. It may be an option if your disease is hard to treat.
This study tests a medication called romiplostim, which helps the body make more blood cells, for children and young adults with severe aplastic anemia. It may help improve blood counts and reduce the need for transfusions.
This trial tests a drug called romiplostim for people with aplastic anemia that did not get better with standard treatments. It aims to boost blood cell counts and may help reduce the need for transfusions.
This study looks at how well a standard combination of two medicines, cyclosporine and eltrombopag, works for people newly diagnosed with aplastic anemia (a condition where the bone marrow doesn't make enough blood cells). It aims to see if this treatment helps improve blood counts and overall outcomes.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.